Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; hyprolose; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; sodium starch glycollate type a; purified talc; hyprolose; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Israel - English - Ministry of Health

novartis israel ltd - valsartan - film coated tablets - valsartan 80 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - English - Ministry of Health

novartis israel ltd - valsartan - film coated tablets - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - English - Ministry of Health

novartis israel ltd - valsartan - film coated tablets - valsartan 40 mg - valsartan - valsartan - diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan significantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; purified talc; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 24.3 mg; valsartan, quantity: 25.7 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; purified talc; colloidal anhydrous silica; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 24.3 mg; valsartan, quantity: 25.7 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; purified talc; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.